Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead

Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead

Metastatic melanoma is the most aggressive and difficult to treat type of skin cancer, with a survival rate of less than 10%. Metastatic melanoma has conventionally been considered very difficult to treat; however, recent progress in understanding the cellular and molecular mechanisms involved in th...

Full description

Bibliographic Details
Main Authors: Tahereh Soltantoyeh, Behnia Akbari, Amirali Karimi, Ghanbar Mahmoodi Chalbatani, Navid Ghahri-Saremi, Jamshid Hadjati, Michael R. Hamblin, Hamid Reza Mirzaei
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cells
Subjects:
metastatic melanoma
chimeric antigen receptor T cells
immunotherapy
Online Access:https://www.mdpi.com/2073-4409/10/6/1450

Similar Items

Similar Items